Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens.

Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens.

Show other versions (1)

Bibliographic Details
Main Authors:	Alexandra U. Scherrer, Jürg Böni, Sabine Yerly, Thomas Klimkait, Vincent Aubert, Hansjakob Furrer, Alexandra Calmy, Matthias Cavassini, Luigia Elzi, Pietro L. Vernazza, Enos Bernasconi, Bruno Ledergerber, Huldrych F. Günthard
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3741402

Similar Items

Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.
by: Alexandra U Scherrer, et al.
Published: (2012-01-01)

Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
by: Alexandra U. Scherrer, et al.
Published: (2013-01-01)

Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients.
by: Alexandra U Scherrer, et al.
Published: (2012-01-01)

Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study.
by: Viktor von Wyl, et al.
Published: (2013-01-01)

Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis
by: Teja Turk, et al.
Published: (2017-09-01)

High Performance Liquid Chromatographic Assay for the Determination of Protease Inhibitors (PIs) and Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in Human Plasma
by: Kantima Sangsiriwut, et al.
Published: (2020-07-01)

The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients.
by: Niko Beerenwinkel, et al.
Published: (2013-01-01)

Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB™) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-Infection
by: Elzi Luigia, et al.
Published: (2011-11-01)

A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA.
by: Gilles Wandeler, et al.
Published: (2011-01-01)

Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics.
by: Denise Kühnert, et al.
Published: (2018-02-01)

Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load.
by: Samuel Alizon, et al.
Published: (2010-09-01)

Intracellular phosphorylation of nucleoside reverse transcriptase inhibitors
by: Sales, Sean Douglas
Published: (2000)

Exploring the clinical pharmacology of the nonnucleoside reverse transcriptase inhibitors
by: Almond, Lisa
Published: (2004)

Reverse transcriptase activity in psoriatic lesions: effects of reverse transcriptase inhibitors on keratinocyte proliferation and differentiation
by: Bonté Frédéric, et al.
Published: (2009-09-01)

Binding of the Nonnucleoside Reverse Transcriptase Inhibitor Efavirenz to HIV-1 Reverse Transcriptase Monomers and Dimers
by: Braz, Valerie Ann
Published: (2009)

Binding of the Nonnucleoside Reverse Transcriptase Inhibitor Efavirenz to HIV-1 Reverse Transcriptase Monomers and Dimers
by: Braz, Valerie Ann
Published: (2010)

Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds.
by: Wan-Lin Yang, et al.
Published: (2015-03-01)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
by: Daniel M. Himmel, et al.
Published: (2020-06-01)

The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort Study
by: Bernard Surial, et al.
Published: (2021-01-01)

Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study
by: Martinetti Gladys, et al.
Published: (2011-01-01)

Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation
by: Dominique L. Braun, et al.
Published: (2020-11-01)

Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART
by: Chenjie Wan, et al.
Published: (2020-11-01)

Informatsionnoe pis'mo
by: - -
Published: (2016-12-01)

Inferring epidemic contact structure from phylogenetic trees.
by: Gabriel E Leventhal, et al.
Published: (2012-01-01)

Lipidic strategy for improving bioavailability of nucleoside HIV reverse transcriptase inhibitor
by: N. S. Shastina, et al.
Published: (2011-04-01)

Reverse Transcriptase Inhibitors Nanosystems Designed for Drug Stability and Controlled Delivery
by: Fedora Grande, et al.
Published: (2019-04-01)

Inhibitors of HIV-1 Reverse Transcriptase—Associated Ribonuclease H Activity
by: Michael A. Parniak, et al.
Published: (2012-10-01)

Development of triazine non-nucleoside reverse transcriptase inhibitors for microbicidal applications
by: Lewi Paul, et al.
Published: (2011-10-01)

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
by: Valeria Famiglini, et al.
Published: (2016-02-01)

Biological evaluation of inhibitors of reverse transcriptase from HIV type-1
by: Hitendra Kumar Lautre, et al.
Published: (2015-01-01)

Isatin thiazoline hybrids as dual inhibitors of HIV-1 reverse transcriptase
by: Rita Meleddu, et al.
Published: (2017-01-01)

Structure-based design of novel inhibitors of HIV-1 reverse transcriptase
by: Hopkins, Andrew Lee
Published: (1998)

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
by: Pei-Ying Wu, et al.
Published: (2017-01-01)

Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
by: Delphine Sculier, et al.
Published: (2020-11-01)

Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort
by: Bernard Surial, et al.
Published: (2019-10-01)

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
by: George W Rutherford, et al.
Published: (2016-01-01)

Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007.
by: Marie Ballif, et al.
Published: (2009-01-01)

Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV.
by: Katharina Kusejko, et al.
Published: (2020-12-01)

Pis'mo v redaktsiyu
by: - -
Published: (2005-08-01)

The Research of Wang Pi’s “Wu”
by: Chieh-Fen Cheng, et al.
Published: (2008)